Alumis Inc.

Health Care
Biotechnology: Pharmaceutical Preparations

Market Cap $173.69M
PE -1
Debt $NaN
Cash $214.44M
EV $NaN
FCF -$217.10M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$242.85M
EBIT	-$245.89M
ROE	-70%
ROA	-60%
FCF	-$217.10M
Equity	$348.39M
Growth Stability	1
PE	-0.72
PB	0.5
P/FCF	-0.8
Price/Cash	1.23
Earnings Growth YoY	157%

Earnings Growth QoQ	65%
Market Cap	$173.69M
Assets	$412.56M
Cash	$214.44M
Shares Outstanding	19.65M
Working Capital	343.83M
Current Ratio	11.26
Shares Growth 3y	22%
Equity Growth QoQ	-179%
Equity Growth YoY	-233%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.

SEC Filings

Direct access to Alumis Inc. (ALMS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30

Sector Comparison

How does Alumis Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Alumis Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Alumis Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Alumis Inc..

Years

Calculation mode

= -$2.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$217M	-$217M	-$217M	-$217M	-$217M	-$217M	-$217M	-$217M	-$217M	-$217M	-$217M	-$2.2B
DCF		-$197M	-$179M	-$163M	-$148M	-$135M	-$123M	-$111M	-$101M	-$92M	-$84M	-$837M
Value	-$2.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	TTM
Net Margins	-
ROA	-60%
ROE	-70%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	TTM
Debt over FCF	-
Debt over Equity	-
Growth Stability	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	CAGR 5Y
Revenue YoY growth	-
Earnings YoY growth	-
Equity YoY growth	-
FCF YoY growth	-